The Skinny on Weight Loss Drugs | Newton

As the obesity epidemic rages across the globe, new weight loss drugs have become so popular that some manufacturers are unable to meet patient demand. Dr. David Katz, founder and CEO of Diet ID, joins Double Take to discuss investment ramifications of these hotly demanded medications.

Presented by

Raphael J. Lewis

Raphael J. Lewis

Head of specialist research

Jack Encarnacao

Jack Encarnacao

Research analyst, investigative, Specialist Research team

Topics

Themes

Related content

Artificial Intelligence: The Second-Order Effects

As AI begins to influence multiple areas beyond technology, we review the latest developments and explore investment opportunities.

October 15, 2024 Brian Blongastainer, Robert C Zeuthen

Getting up to Speed: The Growth of Real-Time Pricing

We investigate the opportunities around the next phase of dynamic pricing.

October 3, 2024 Robert C Zeuthen, Shivam Kollur

Inflation, Debt and Rates: The Trinity Defining Markets

We assess the current and potential future impact of inflation, debt and interest rates upon markets.

June 21, 2024 Newton fixed income team

See all insights

Explore topics